CD38 and neoplasm: In addition to a single antibody targeting CD38, a novel anti-CD38 /CD3 bi-specific T cell recruitment antibody AMG-424 has been discovered in recent years, which can kill cancer cells expressing high and low levels of CD38 in vitro and trigger T cell proliferation, and induce tumor growth inhibition and consumption of peripheral B cells in vivo.